ArticleThe pharmacogenomics journal2026
FTO rs7195994 Is associated with TNF inhibitor response in lean rheumatoid arthritis patients: A BMI-stratified pharmacogenetic analysis.
Article in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor necrosis factor inhibitors (TNFi) have transformed the management of rheumatoid arthritis (RA); however, up to 40% of patients fail to achieve an adequate clinical response. Current clinical predictors remain insufficient, highlighting the need for pharmacogenetic biomarkers to guide biologic therapy selection. In this study, we investigated genetic variants associated with TNFi treatment response, with a particular focus on body mass index (BMI)-dependent effects, using a large real-world cohort. A total of 519 patients with RA were identified from the Taiwan Precision Medicine Initiative (TPMI), an electronic health record-linked biobank. Eligible patients had received TNFi therapy for at least 6 months and had available genotyping data. Ninety-seven candidate single nucleotide polymorphisms (SNPs) previously reported to be associated with TNFi response were identified through a systematic literature search. Five variants located in immune-metabolic genes (FTO, ZNF618, RANK, CD84, and LOC105375523) were further analyzed using univariable and multivariable logistic regression models. Subgroup analyses stratified by BMI were performed to explore potential effect modification. Three variants-FTO rs7195994, ZNF618 rs16911006, and LOC105375523 rs834811-were significantly associated with TNFi response in initial analyses. In multivariable models, only FTO rs7195994 remained an independent predictor of non-response (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.22-0.87; p = 0.019). Among patients with BMI < 27 kg/m², carriers of the rs7195994 risk allele had a 49% lower likelihood of achieving treatment response (OR 0.51, 95% CI 0.28-0.92; p = 0.0249), whereas no significant association was observed in patients with higher BMI. These findings identify FTO rs7195994 as a novel, BMI-modulated pharmacogenetic marker of TNFi non-response in RA. Incorporating BMI-stratified genetic profiling into clinical decision-making may facilitate early identification of patients unlikely to benefit from TNFi therapy, thereby supporting precision treatment strategies. Further validation in multiethnic populations and functional studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.